LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced that three abstracts have been accepted for presentations, which include two poster presentations and one oral presentation, at the 52nd European Association for the Study of Diabetes Annual meeting, to be held September 12th – 16th in Munich, Germany.
Poster and Oral Presentation Information
Poster # 717
Title: “Imeglimin Improves Vascular Dysfunction in Type 2
Diabetes Animal Models
Session Name: PS 063 Novel agents
Date,
Time & Location: Wednesday, September 14, 2016, 12:00 PM, Poster
Hall
Poster # 724
Title: “PXL770, a Novel Direct AMPK Activator, Inhibits
Hepatic de novo Lipogenesis for the Treatment of Metabolic Disorders”
Session
Name: PS 063 Novel agents
Date, Time & Location:
Wednesday, September 14, 2016, 12:50 PM, Poster Hall
Oral Presentation # 113
Title: “PXL770, a Novel Direct AMPK Activator, Improves
Metabolic Disorders in Diet Induced Mice Model of Obesity and Diabetes”
Session
Name: OP 19 Diabetes drugs of the future
Date, Time &
Location: Wednesday, September 14, 2016, 3:30 PM, Minkowski Hall
Poxel will announce the results through a press release after the presentations.
About Imeglimin
Imeglimin is the first in a new chemical class of oral anti-diabetic agents, the Glimins. Imeglimin acts on three main target organs involved in glucose homeostasis: the liver, muscle, and the pancreas. Imeglimin’s unique mechanism of action targets the mitochondria bioenergetics. This distinct mode of action compared to existing treatments for type 2 diabetes makes Imeglimin a prime candidate in monotherapy and to complement other treatments such as metformin or sitagliptin.
About PXL770
PXL770 directly activates adenosine monophosphate-activated protein kinase (AMPK), an enzyme that acts as an energy sensor and regulator, maintaining cellular homeostasis, thus playing an important role in the management of diabetes. In addition to its anti-diabetic properties, PXL770 has the potential to treat lipid-related abnormalities, which are present in a vast majority of diabetic patients and are the cause of cardiovascular incidents among this population, as well as other metabolic disorders.
About Poxel
Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 trials for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the United States and Europe and have fully enrolled a Phase 2b clinical study in Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)
View source version on businesswire.com: http://www.businesswire.com/news/home/20160905005456/en/
Poxel SA
Jonae R. Barnes, +1 617-818-2985
Senior
Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
or
Investor
relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen
Schweitzer, + 49 89 2424 3494
or
Stephanie May, + 49 175 571
1562
smay@macbiocom.com
or
Investor
relations / Media - France
NewCap
Florent Alba/Nicolas
Mérigeau, + 33 1 44 71 98 55
poxel@newcap.fr
Source: POXEL SA
Released September 6, 2016